Associate Professor Richard Haynes
- 3C: A CAMPATH, Calcineurin inhibitor reduction and Chronic allograft nephropathy trial
- ASCEND: A Study of Cardiovascular Events iN Diabetes
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- Trials Methodology
- UK HARP III
- EMPA-KIDNEY: the study of heart and kidney protection with empagliflozin
- MRC Project Leader Track
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.
PCSK9 inhibition: ready for prime time in CKD?
Mafham M. and Haynes R., (2018), Kidney Int, 93, 1267 - 1269
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.
Herrington W. et al, (2018), Kidney International
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Parish S. et al, (2018), Circ Genom Precis Med, 11
The Role of Lipoprotein(a) in Chronic Kidney Disease.
Hopewell JC. et al, (2018), Journal of lipid research
ELECTIVE CONVERSION TO SIROLIMUS VS. CONTINUED TACROLIMUS IN KIDNEY TRANSPLANTATION (THE 3C STUDY): RESULTS OF A RANDOMIZED TRIAL
Haynes R. et al, (2017), TRANSPLANT INTERNATIONAL, 30, 63 - 64